Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prospective Comparison of Cirrus Versus Stratus Ocular Coherence Tomography for Different Retinal Pathology.

This study has been completed.
Sponsor:
Collaborator:
Research to Prevent Blindness
Information provided by (Responsible Party):
University of Chicago
ClinicalTrials.gov Identifier:
NCT00731458
First received: August 6, 2008
Last updated: September 4, 2013
Last verified: September 2013
  Purpose

Ocular Coherence Tomography (OCT) is a non-invasive ophthalmologic test that uses reflected, unheated, non-concentrated visible light in order to scan and provide a 2-dimensional topographic analysis of the retina and optic nerve. It has wide diagnostic utility especially in patients with clinically significant macular edema, glaucoma, and other retinal eye diseases. At the University of Chicago, we have utilized the Stratus brand OCT (Carl Zeiss Inc) for the past 5 years. Recently we have acquired a beta version of the company's new model, the Cirrus HD-OCT (Carl Zeiss Inc.) which features improved resolution, shorter scanning time and a more user-friendly interface. The purpose of this study is to compare findings between the two models in patients with different common and uncommon eye diseases, including diabetic macular edema, glaucoma and age-related macular degeneration. We hypothesis that the Cirrus OCT is able to accurately quantify eye pathology compared to Stratus OCT.


Condition Intervention
Retinal Pathology
Device: Optical coherance tomography ( Cirrus; Stratus)

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: Prospective Comparison of Cirrus and Stratus Optical Coherence Tomography for Quantifying Retinal Thickness

Further study details as provided by University of Chicago:

Enrollment: 60
Study Start Date: May 2007
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Optical coherance tomography ( Cirrus; Stratus)
    Non-contact retinal thickness analyzer
    Other Name: OCT; Cirrus; Stratus
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Any eye pathology that may cause macular edema.

Exclusion Criteria:

  • Vitreous media opacities including dense cataracts, vitreous hemorrhage, and corneal opacities
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00731458

Sponsors and Collaborators
University of Chicago
Research to Prevent Blindness
Investigators
Principal Investigator: Seenu Hariprasad, M.D. University of Chicago
  More Information

Publications:
Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT00731458     History of Changes
Other Study ID Numbers: 15606B
Study First Received: August 6, 2008
Last Updated: September 4, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Chicago:
OCT;
Cirrus;
Stratus;
macular thickness

ClinicalTrials.gov processed this record on November 25, 2014